## **KISUNLA™** Referral Form

## **Fax Completed Form To:**

Phone:



		PATIEN	T INFORMATION				
Patient Name:					Date of Birth:		
Referral Date:	□ New Referral □ Updated Order □ Order Renewal						
Address:	City/State/Zip:						
Home Phone:		Cell Phone:			Work Phone:		
Secondary Contact:		Height:	Weight:		│ □ Male □ Female		
Allergies:							
Current Medications:							
Other Medical Conditions or Additional Comments:  Medical History Polated to IV Inscrition (e.g. lymph podes or mastertomy):							
Medical History Related to IV Insertion (e.g. lymph nodes or mastectomy):  DIAGNOSIS							
Patient Diagnosis & ICD-10: G30.0 - Alzheimer's disease with early onset G30.1 - Alzheimer's disease with late onset G30.8 - Other Alzheimer's disease							
G30.9 - Alzheimer's disease, unspecified G31.84 - Mild cognitive impairment							
Prescriber must indicate the following requirements have been met to confirm diagnosis & that Patient has evidence of AD neuropathology & has been assessed for baseline ARIA risk via MRI:							
Amyloid pathology confirmed via: ☐ Amyloid PET Scan <b>-OR-</b> ☐ CSF Analysis <b>-OR-</b> ☐ Blood plasma Result: ☐ Amyloid positive ☐ Amyloid negative (Kisunla™ is not a treatment option for this Patient, if checked)  Date:							
□ Recent MRI obtained prior to initiating Kisunla™ (including FLAIR and T2/GRE or SWI) to assess ARIA risk □ Prescriber has verified that this Patient does not have evidence of prior ARIA-H  Date:							
☐ Completion of cognitive assessment type: ☐ MMSE ☐ MoCA ☐ CDR ☐ Other:  Score:					Date:		
☐ Completion of functional assessment type: ☐ FAQ ☐ FAST ☐ Other:					Date:		
☐ Results for ApoE Testing					Date:		
☐ Completion of CMS approved CED registry (only required for Patients with Medicare) ClinicalTrials.gov Registry Number: NCT Submission Number (if applicable): CED Submission Date:							
Note: MRIs must be obtained prior to initial infusion to assess ARIA risk. During treatment, conduct an ARIA monitoring MRI before Infusions 2, 3, 4 and 7 and if symptoms consistent with ARIA occur.							
PROVIDER INFORMATION							
Physician Name: Lic#:				DEA #:			
Practice Name: Address:				NPI#:			
				City/State/Zi	y/State/Zip:		
Office Contact: Phone: Fax: Supervisory Physician (if applicable):							
Supervisory Physician (if applicable):  PLEASE ATTACH							
☐ Patient demographics & front/back copy of all insurance cards (prescription & medical) ☐ Recent office visit notes, history & physical, lab & pertinent procedure results ☐ Letter of medical necessity if drug dosing or indication is outside of FDA guidelines							
☐ Current medication list & list of prior medications tried and failed (with dates) ☐ Line access documentation/verification if applicable							
NURSING & LAB ORDERS							
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders.							
Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mL0R 10units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line Lab Orders:							
PRESCRIPTION ORDERS							
Anaphylaxis Kit: (Check all that apply)							
Pre-Medications:       ☐ Acetaminophenmg POminutes prior to infusionSolu-Medrolmg IVminutes prior to infusionmg IVminutes prior to infusionmg IVminutes prior to infusionmg IVminutes prior to infusionmg IVminutes prior to infusion							
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary							
PRODUCT PRESCRIPTION INFORMATION						REFILLS	
Is this a first dose?							
☐ KISUNLA	☐ Induction ramp up: Week 0: 350mg IV infusion, Week 4: 700mg IV infusion, Week 8: 1050mg IV infusion via ☐ gravity — OR — ☐ pump over 30 minutes					NONE	
	☐ Maintenance: Week 12 and every 4 weeks thereafter: 1400mg IV infusion via ☐ gravityOR ☐ pump over 30 minutes ☐						
	If missed dose, administer the same dose as soon as possible and continue every 4 weeks.  Obtain MRI prior to 2nd, 3rd, 4th, and 7th infusions. MRI results must be performed and cleared by MD to proceed to next infusion.						
□ OTHER						NONE	
By signing this form and utilizing our services, you are authorizing Amerita to assist with prior authorization requests acting as your pharmacy provider in dealing with medical and prescription insurance companies							

Prescriber's Signature Dispense as Written

**Print Name** 

Date

Prescriber's Signature **Substitution Permitted**  Print Name

Date



